Abbott Labs Spins Off Nutrition Unit: What It Means for ABT Stock

Oct 26, 2026

Bobby Quant Team

💡 Key Takeaway

Abbott's decision to spin off its troubled nutrition business should sharpen its focus on high-growth medical devices and diagnostics, reinforcing its long-term dividend growth story.

Abbott's Strategic Spin-Off and Solid Q3 Results

Abbott Laboratories reported third-quarter results on Oct. 21, with sales of $13 billion, up 7% year over year on a comparable basis, and adjusted earnings per share of $1.42, up 9%. The company's medical device and pharmaceutical segments drove growth, while nutrition lagged with just 4.9% growth.

Alongside the earnings, Abbott announced it will spin off its nutrition segment into a standalone company. This segment has faced headwinds, including a 2022 infant formula recall and lawsuits related to its premature infant formula products, which have weighed on sales growth.

The spin-off is part of Abbott's broader strategy to streamline operations and focus on higher-margin businesses. The company also recently closed its $21 billion acquisition of Exact Sciences, adding cancer diagnostics to its portfolio.

Abbott's medical device segment remains a key growth engine, with diabetes care sales of $2.2 billion in Q3, driven by its FreeStyle Libre continuous glucose monitoring system. Management sees significant room for growth as the CGM market remains underpenetrated.

What This Means for Me

If you hold ABT, the spin-off could unlock value as the nutrition business becomes a separate entity, potentially leading to a higher valuation for the remaining company. Investors with exposure to healthcare or dividend-focused portfolios may benefit from Abbott's continued dividend growth and defensive characteristics. However, monitor the spin-off execution and any lingering legal issues from the nutrition segment.

Why the Spin-Off and Pipeline Point to a Brighter Future

The spin-off allows Abbott to shed a segment that has been a drag on growth and mired in legal challenges. By separating nutrition, Abbott can focus on its core medical device and diagnostics businesses, which offer higher growth and margins.

The Exact Sciences acquisition positions Abbott in the fast-growing cancer diagnostics market, with Cologuard as a key asset. This diversification into diagnostics complements Abbott's existing device portfolio and opens new revenue streams.

Abbott's FreeStyle Libre franchise continues to perform well, and the company estimates that only a fraction of diabetes patients who could benefit from CGM are currently using the technology. This underpenetration suggests a long runway for growth.

For income investors, Abbott's status as a Dividend King—with over 50 consecutive years of dividend increases—remains intact. The spin-off could unlock value and support continued dividend growth as the remaining businesses become more profitable.

Stock to Watch

Stocks	Impact	Analysis
ABT	Positive	The spin-off of the nutrition segment should improve Abbott's growth profile and margins, while the medical device and diagnostics businesses offer strong long-term growth potential.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.